Waltham, MA, United States of America

Xin Zhang

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Enanta Pharmaceuticals, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xin Zhang. Retrieved from https://idiyas.com/inventor/xin-zhang-tn1cfcf0

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Xin Zhang’s Patent Work in Pharmaceutical Innovation.

Introduction

Xin Zhang is an inventor associated with Waltham, Massachusetts, and Enanta Pharmaceuticals, Inc. The supplied information identifies one patent associated with Zhang.

Latest Patents

Zhang’s patent, “Processes for the Preparation of Substituted Spirooxindole Derivatives,” describes processes for preparing a compound of Formula (A), or a pharmaceutically acceptable salt or solvate thereof. The compound and related pharmaceutical compositions are described as useful as SARS-CoV-2 3CL protease inhibitors. Zhang is credited with 1 patent.

Career Highlights

The available information connects Zhang’s patent work to Enanta Pharmaceuticals, Inc., a company involved in pharmaceutical research and development. The patent focuses on preparing compounds with potential application as SARS-CoV-2 3CL protease inhibitors.

Collaborations

Kaicheng Zhu and Tao Wang are identified as Zhang’s coworkers.

Conclusion

Xin Zhang’s listed patent reflects work on processes for preparing spirooxindole derivatives with potential pharmaceutical applications, including as SARS-CoV-2 3CL protease inhibitors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…